论文部分内容阅读
目的分析脑卒中后抑郁症患者采用奥氮平治疗的临床价值及可行性。方法将脑卒中后抑郁症患者140例随机分为观察组和对照组各70例。观察组予以奥氮平治疗,对照组予以氟西汀治疗,治疗前后采用神经功能缺损(NIHSS)评分、抑郁自评量表(SDS)评分和汉密顿抑郁量表(HAMD)评分评估患者的神经功能缺损程度及抑郁状况。对比2组药物不良反应及治疗后生活质量评分。结果治疗后2组NIHSS评分、SDS评分及HAMD评分均低于治疗前,且观察组低于对照组;观察组患者的不良反应发生率为4.29%低于对照组的15.71%;观察组患者治疗后饮食评分、睡眠评分及精神状态评分均明显高于对照组患者,差异均有统计学意义(P<0.05)。结论奥氮平用于脑卒中后抑郁症临床治疗中的效果显著,可有效改善患者的负性情绪,提高患者的生活质量,值得推广。
Objective To analyze the clinical value and feasibility of using olanzapine in patients with post-stroke depression. Methods One hundred and seventy patients with post-stroke depression were randomly divided into observation group (70 cases) and control group (70 cases). The observation group was treated with olanzapine and the control group was treated with fluoxetine. The scores of NIHSS, SDS and HAMD were evaluated before and after treatment Neurological deficit and depression status. Adverse reactions and quality of life after treatment were compared between the two groups. Results After treatment, NIHSS score, SDS score and HAMD score of two groups were lower than before treatment, and the observation group was lower than the control group; the incidence of adverse reactions in the observation group was 4.29% lower than the control group of 15.71% Postprandial diet scores, sleep scores and mental status scores were significantly higher than the control group, the difference was statistically significant (P <0.05). Conclusion Olanzapine is effective in the clinical treatment of depression after stroke, which can effectively improve the negative emotions of patients and improve the quality of life of patients, which deserves promotion.